Literature DB >> 20375806

Unfavorable prognosis of small cell neuroendocrine carcinoma of the uterine cervix: a retrospective matched case-control study.

Shin Wha Lee1, Joo-Hyun Nam, Dae-Yeon Kim, Jong-Hyeok Kim, Kyu-Rae Kim, Yong-Man Kim, Young-Tak Kim.   

Abstract

OBJECTIVES: This study was a matched case-control study to analyze the clinical and pathological characteristics and the prognosis of patients with small cell neuroendocrine carcinoma in the uterine cervix. PATIENTS AND METHODS: Thirty-two patients were treated for small cell neuroendocrine carcinoma of the cervix (SCNEC) at Asan Medical Center between January 1996 and June 2008. For a 1-to-2 matched case-control study, 64 patients with squamous cell carcinoma of the cervix (SCC) whose clinical stage and age are consistent with the SCNEC group were selected. Medical records were retrospectively reviewed to analyze and compare the clinical and pathological outcomes.
RESULTS: In the SCNEC group, the median age was 45 years, and early stage (stage IIA or below) was 75.0%. The postoperative adjuvant therapy was given more frequently in the SCNEC group. The recurrence rate was 59.4%, and lung, bone, and liver were common sites in the SCNEC group. Parametrial involvement and lymphovascular space invasion were risk factors in the SCNEC group, whereas lymph node metastasis is the risk factor in the SCC group. The progression-free survival and overall survival were significantly shorter in the SCNEC group than in the SCC group (16.9 and 30.6 months vs 47.7 and 49.1 months, P < 0.05). Interestingly, survival outcomes in the early stage of SCNEC were remarkably worse than those of SCC and almost identical to those of the advanced stage of SCNEC.
CONCLUSION: We confirmed the unfavorable prognosis related to hematogenous metastasis in SCNEC. The treatment modality of early-stage SCNEC, which is radical hysterectomy followed by adjuvant therapy, needs to be reevaluated.

Entities:  

Mesh:

Year:  2010        PMID: 20375806     DOI: 10.1111/IGC.0b013e3181ce427b

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  14 in total

1.  Brachytherapy and survival in small cell cancer of the cervix and uterus.

Authors:  Alexander J Lin; Comron Hassanzadeh; Stephanie Markovina; Julie Schwarz; Perry Grigsby
Journal:  Brachytherapy       Date:  2018-12-15       Impact factor: 2.362

2.  [S3 guidelines on diagnostics and treatment of cervical cancer: Demands on pathology].

Authors:  L-C Horn; M W Beckmann; M Follmann; M C Koch; P Mallmann; S Marnitz; D Schmidt
Journal:  Pathologe       Date:  2015-11       Impact factor: 1.011

3.  Natural history and outcome of neuroendocrine carcinoma of the cervix.

Authors:  Benjamin Margolis; Ana I Tergas; Ling Chen; June Y Hou; William M Burke; Jim C Hu; Cande V Ananth; Alfred I Neugut; Dawn L Hershman; Jason D Wright
Journal:  Gynecol Oncol       Date:  2016-02-09       Impact factor: 5.482

4.  A case of primary uterine cervical neuroendocrine tumor with meningeal carcinomatosis confirmed by diagnostic imaging and autopsy.

Authors:  Shinichi Komiyama; Eiji Nishio; Yutaka Torii; Kyoko Kawamura; Shuko Oe; Rina Kato; Kiyoshi Hasagawa; Masato Abe; Makoto Kuroda; Yasuhiro Udagawa
Journal:  Int J Clin Oncol       Date:  2010-12-15       Impact factor: 3.402

5.  Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) - Part 2 with Recommendations on Psycho-oncology, Rehabilitation, Follow-up, Recurrence, Palliative Therapy and Healthcare Facilities.

Authors:  Tanja Fehm; Frederik A Stübs; Martin C Koch; Peter Mallmann; Christian Dannecker; Anna Dietl; Anna Sevnina; Franziska Mergel; Laura Lotz; Anne Ehret; Daniel Gantert; Franca Martignoni; Jan-Philipp Cieslik; Jan Menke; Olaf Ortmann; Carmen Stromberger; Karin Oechsle; Beate Hornemann; Friederike Mumm; Christoph Grimm; Alina Sturdza; Edward Wight; Kristina Loessl; Michael Golatta; Volker Hagen; Timm Dauelsberg; Ingo Diel; Karsten Münstedt; Eberhard Merz; Dirk Vordermark; Katja Lindel; Christian Wittekind; Volkmar Küppers; Ralph Lellé; Klaus Neis; Henrik Griesser; Birgit Pöschel; Manfred Steiner; Ulrich Freitag; Tobias Gilster; Alexander Schmittel; Michael Friedrich; Heidemarie Haase; Marion Gebhardt; Ludwig Kiesel; Michael Reinhardt; Michael Kreißl; Marianne Kloke; Lars-Christian Horn; Regina Wiedemann; Simone Marnitz; Anne Letsch; Isabella Zraik; Bernhard Mangold; Jochen Möckel; Céline Alt; Pauline Wimberger; Peter Hillemanns; Kerstin Paradies; Alexander Mustea; Dominik Denschlag; Ulla Henscher; Reina Tholen; Simone Wesselmann; Matthias W Beckmann
Journal:  Geburtshilfe Frauenheilkd       Date:  2022-02-11       Impact factor: 2.915

6.  Prognostic factors and treatment comparison in early-stage small cell carcinoma of the uterine cervix.

Authors:  W J Tian; M Q Zhang; R H Shui
Journal:  Oncol Lett       Date:  2011-10-12       Impact factor: 2.967

7.  Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation.

Authors:  Yasmin A Lyons; Michael Frumovitz; Pamela T Soliman
Journal:  Gynecol Oncol Rep       Date:  2014-10-25

8.  Case report: term birth after fertility-sparing treatments for stage IB1 small cell neuroendocrine carcinoma of the cervix.

Authors:  Pei-Ying Wu; Ya-Min Cheng; Geok Huey New; Cheng-Yang Chou; Chun-Ting Chiang; Hung-Wen Tsai; Yu-Fang Huang
Journal:  BMC Womens Health       Date:  2017-07-28       Impact factor: 2.809

9.  Enhanced efficacy of adjuvant chemotherapy and radiotherapy in selected cases of surgically resected neuroendocrine carcinoma of the uterine cervix: A retrospective cohort study.

Authors:  Sixia Xie; Liang Song; Fan Yang; Chendian Tang; Shaoyan Yang; Ji He; Xiaoling Pan
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

Review 10.  Influence of clinicopathological characteristics and comprehensive treatment models on the prognosis of small cell carcinoma of the cervix: A systematic review and meta-analysis.

Authors:  Qian Zhang; Yao Xiong; Jiaxiang Ye; Liying Zhang; Li Li
Journal:  PLoS One       Date:  2018-04-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.